You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,517,253


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,517,253
Title:Compositions for treating multiple sclerosis
Abstract: Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.
Inventor(s): Foussat; Arnaud (Biot, FR)
Assignee: TXCELL (Valbonne, FR)
Application Number:12/738,706
Patent Claims:1. A method for diminishing the loss of motor function and/or diminishing inflammation of the central nervous system in a human subject in need thereof, the method consisting of: administering to said subject an effective amount of a pharmaceutical composition consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen, in combination with one or more pharmaceutically acceptable carrier, or a medicament consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen, wherein said human multiple sclerosis-associated antigen is myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein, proteolipid protein, or a mixture thereof, and the pharmaceutical composition or medicament comprises Tr1cells autologous to the cells of the subject.

2. The method according to claim 1, wherein 10.sup.4/kg to 10.sup.9/kg Tr1 cells are administered to the subject in need thereof.

3. The method according to claim 1, wherein said subject does not respond adequately to, or is unlikely to respond adequately to, one or more therapeutic agents selected from the group consisting of interferon-beta, glatiramer acetate, mitoxantrone, cyclophosphamide, methotrexate, aziathropine, and natalizumab.

4. The method according to claim 1, wherein said human multiple sclerosis-associated antigen is myelin oligodendrocyte protein.

5. The method according to claim 1, wherein the subject is HLA-DR2 positive, and wherein said human multiple sclerosis-associated antigen is selected from the group consisting of: MOG 35-55, MOG 21-40, MOG 41-60, MOG 71-90, MOG 81-100, MOG 111-130, and MOG 63-37 peptides.

6. The method according to claim 1, wherein the subject is HLA-DR4 positive, and wherein said human multiple sclerosis-associated antigen is selected from the group consisting of: MOG 21-40, MOG 97-108, and MOG 181-200 peptides.

7. A method for diminishing the loss of motor function and/or diminishing inflammation of the central nervous system in a human subject in need thereof, comprising: administering to said subject an effective amount of a pharmaceutical composition consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen in combination with one or more pharmaceutically acceptable carrier, or a medicament consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen, optionally in combination with one or more therapeutic agent used for treating multiple sclerosis, wherein said human multiple sclerosis-associated antigen is myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein, proteolipid protein, or a mixture thereof, said administration is without co-administration of the soluble antigen, and the medicament or pharmaceutical composition comprises Tr1 cells autologous to the cells of said subject.

8. The method according to claim 7, wherein the administration to said subject of the effective amount of the medicament or the pharmaceutical composition is in combination with one or more therapeutic agent used for treating multiple sclerosis.

9. The method according to claim 8, wherein said one or more therapeutic agent is selected from the group consisting of interferon-beta, glatiramer acetate, mitoxantrone, cyclophosphamide, methotrexate, aziathropine, and natalizumab.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.